That’s the point. You start out with hamsters then move to people. The CEO will be presenting these results at the San Francisco JP Morgan Biotech conference tomorrow.
“The presentation will focus on recent successful preclinical in vivo trial results of BiondVax’s inhaled COVID-19 therapy, and additional pipeline plans including a nanosized VHH-antibody (NanoAb) targeting IL-17 for the treatment of autoimmune diseases such as psoriasis and additional NanoAbs for the treatment of additional autoimmune diseases such as asthma, psoriatic arthritis and macular degeneration.”
They just about wiped out COVID in hamsters. I’d think something like that would be interesting for potential investors.
If that isn’t enough BVXV just received a $57 per share valuation from Zack’s small cap research. That’s almost 20x its current SP.
News 
Market Data 
Discover 
